Libertyville, IL, United States of America

Marc J Scanio

USPTO Granted Patents = 20 (Patent Applications = 9)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 9.8

ph-index = 4

Forward Citations = 94(Granted Patents)

Location History:

Lindenhurst, IL (US) (2012 - 2018)
Libertyville, IL (US) (2016 - 2019)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2012-2019

Loading Chart...

20 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10508113 - Inhibitors of tyrosine kinase 2 mediated signaling (2019-12-17),

2. 10399940 - Substituted pyrrolidines and methods of use (2019-09-03),

3. 10118916 - Modulators of cystic fibrosis transmembrane conductance regulator protein (2018-11-06),

4. 9983218 - Indole and indoline derivatives and methods of use thereof (2018-05-29),

5. 9981910 - Substituted pyrrolidines and methods of use (2018-05-29),

6. 9969693 - 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use (2018-05-15),

7. 9840513 - Substituted tricyclics and method of use (2017-12-12),

8. 9783527 - Indazole ureas and method of use (2017-10-10),

9. 9777020 - Furo-3-carboxamide derivatives and methods of use (2017-10-03),

10. 9625475 - Indole and indoline derivatives and methods of use thereof (2017-04-18),

11. 9452986 - 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use (2016-09-27),

12. 9133206 - Benzodiazepine and pyridodiazepine derivatives (2015-09-15),

13. 9063126 - Indole and indoline derivatives and methods of use thereof (2015-06-23),

14. 8987453 - Azaadamantane derivatives and methods of use (2015-03-24),

15. 8962639 - Potassium channel modulators (2015-02-24),

Title: The Innovative Contributions of Marc J. Scanio

Introduction

Marc J. Scanio, based in Libertyville, IL, has made significant strides in the realm of pharmaceutical innovations, amassing an impressive portfolio of 20 patents. His work primarily focuses on developing compounds that play a crucial role in the treatment of various medical conditions.

Latest Patents

Among his latest patents, Scanio has contributed to the field with two notable innovations. The first, titled "Inhibitors of Tyrosine Kinase 2 Mediated Signaling," discloses compounds of Formula (I) and their pharmaceutically acceptable salts. This patent covers pharmaceutical compositions and methods of preparation and use, addressing critical pathways in cell signaling. The second patent, "Substituted Pyrrolidines and Methods of Use," reveals compounds of Formula (I) with potential applications in treating cystic fibrosis. This invention includes methods for production, pharmaceutical compositions, and treatment procedures to improve patients' health.

Career Highlights

Throughout his career, Marc J. Scanio has made significant contributions while working with organizations like AbbVie Inc. and AbbVie S.à r.l. His experience in these esteemed companies has allowed him to focus on innovative research and practical applications of his inventions. His work has not only led to numerous patents but also to advancements in medical treatments.

Collaborations

Collaboration has been a vital aspect of Scanio's journey. He has worked alongside notable colleagues such as William H. Bunnelle and Lei Shi, contributing to an environment of shared knowledge and innovation, which has enhanced the impact of his work on drug development.

Conclusion

Marc J. Scanio's dedication to pharmaceutical research and innovation has established him as a prominent figure in the field. His extensive patent portfolio and collaborative efforts reflect his commitment to improving healthcare through groundbreaking inventions. As he continues to develop new and effective treatments, his contributions will undoubtedly leave a lasting legacy in the realm of medicine.

This text is generated by artificial intelligence and may not be accurate.